Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies ...
Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 ...
Your vote is important no matter how many securities of the Company you hold. The Board recommends that Securityholders vote FOR the Arrangement Resolution. In light of the current Canada Post strike, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback